Acquisition

A breakthrough genetic therapy for ALS offers hope, but a split verdict from Canadian health agencies reveals the tough calculus of innovation versus cost.

With a 2026 decision date set, Lifezone Metals is de-risking a world-class nickel project in Tanzania, promising to shake up the global battery supply chain.

Apollo Silver plans to revive a massive California silver deposit, aligning with US strategic goals. Can it overcome technical and environmental hurdles?

The U.S. Coast Guard taps AeroVironment for advanced underwater robots, a key step in its Force Design 2028 plan to boost safety and mission efficiency.

As agencies retool for a complex market, Bastion's appointment of a cultural PR expert highlights a critical shift for pharma and beyond.

Bristol Myers Squibb's Opdivo gets FDA priority review, backed by landmark data suggesting it could unseat a key competitor as the new gold standard.

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

As EVgo nears breakeven, it brings in a seasoned financial architect from the energy sector to steer its capital-intensive buildout toward profitability.

A single crypto campaign generates $53.5B in futures volume. We dissect MEXC's strategy and what it reveals about the exchange wars and token adoption.

Bill Ackman's fund posted a stellar 24.1% return. We dive into the high-conviction plays and innovative structure driving this market-beating performance.

OMRON's new global ECG strategy leverages AI and key acquisitions to tackle heart disease, aiming to eliminate adverse cardiovascular events.

A new contract for TGS in Brazil signals enduring appeal for offshore oil. Discover how 4D seismic is unlocking value in mature, complex energy fields.

A Belgian med-tech firm is replacing a centuries-old procedure with an implantable pump, targeting a growing multi-billion dollar liver disease market.

The industrial giant secured a rare dual 'A' rating from CDP. We decode what this means for its strategy, competitors, and ESG-focused investors.

With two key drug approvals, Sanofi isn't just treating rare diseases in China; it's executing a playbook that redefines market entry and dominance.

A rival bid reshaped a major gold merger, creating a West African powerhouse. Here’s how the deal was saved and what it means for the market.

Stewart Information Services is raising millions via a stock offering. We analyze the strategy, the market signals, and the impact on shareholder value.

With rare dual Google accreditations, Audiencerate offers a blueprint for privacy-first advertising in a world without third-party cookies.

BTCC's integration with TradingView signals a major industry shift, bringing professional-grade tools and seamless execution to the crypto futures market.

The return of a pharma-finance veteran to MediPharm's board isn't just a personnel change; it's a strategic move to secure its global pharmaceutical ambitions.